MREO Mereo BioPharma Group plc
Pharmaceutical Preparations · Nasdaq · SEC CIK 1719714 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY35.2%
TTM EPS YoY40.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-76.6%
ROA-64.8%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets19.8%
Debt / equity0.00x
Current ratio5.22x
Interest coverage-440.64x
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-11.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $500,000 | $0 |
| R&D expense | $17.77M | $20.93M |
| SG&A expense | $23.01M | $26.43M |
| Operating income | -$40.11M | -$47.36M |
| Interest expense | $255,000 | $1.37M |
| Pretax income | -$41.88M | -$43.25M |
| Income tax | $0 | $0 |
| Net income | -$41.88M | -$43.25M |
| EBITDA | -$39.95M | -$47.22M |
| EPS (basic) | -0.05 | -0.06 |
| EPS (diluted) | -0.05 | -0.06 |
| Weighted avg. shares (diluted) | 797.12M | 739.62M |
| Balance sheet | ||
| Cash & equivalents | $40.99M | $69.80M |
| Current assets | $45.02M | $74.76M |
| PP&E, net | $137,000 | $257,000 |
| Intangibles | $516,000 | $643,000 |
| Total assets | $45.92M | $76.39M |
| Current liabilities | $4.30M | $13.85M |
| Total liabilities | $5.00M | $15.42M |
| Shareholders' equity | $40.92M | $60.97M |
| Cash flow statement | ||
| Operating cash flow | -$30.97M | -$32.83M |
| Capital expenditure | $20,000 | $0 |
| Free cash flow | -$30.99M | -$32.83M |
| Investing cash flow | -$20,000 | -$699,000 |
| Financing cash flow | $327,000 | $46.15M |
| Depreciation & amortization | $157,000 | $143,000 |
| Stock-based compensation | $7.60M | $7.39M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.